How Much Does Wegovy Actually Cost in 2026? The Complete Price Breakdown for Pills, Pens, and Compounded Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's list price is $1,349.02 per month for the injection pen, but actual out-of-pocket costs range from $0 to $1,349 depending on insurance coverage and manufacturer savings programs
• Most commercial insurance plans cover Wegovy for weight loss as of 2026, but Medicare and Medicaid coverage remains limited by federal law
• Compounded semaglutide (the same active ingredient as Wegovy) costs $297 to $450 per month and is legal during the FDA shortage period, offering identical mechanism of action at 78% lower cost
• The "pill" search reflects a common misconception: Wegovy comes only as a weekly injection pen, though oral semaglutide (Rybelsus) exists as a separate daily pill formulation at different dosing

Direct answer (40-60 words)

Wegovy costs $1,349.02 per month at list price for the once-weekly injection pen. With commercial insurance and manufacturer copay cards, out-of-pocket costs drop to $0 to $25 per month for eligible patients. Without insurance, compounded semaglutide offers the same active ingredient for $297 to $450 monthly during the ongoing FDA shortage period.

Table of contents

1. What most articles get wrong about Wegovy pricing
2. The list price vs actual cost breakdown
3. Insurance coverage in 2026: commercial, Medicare, and Medicaid
4. The Novo Nordisk savings card: who qualifies and what it covers
5. Compounded semaglutide as a legal alternative during shortages
6. Why "Wegovy pill" is a misnomer (and what oral semaglutide actually is)
7. The FormBlends cost-access decision tree
8. When paying out-of-pocket makes financial sense
9. Prior authorization: the hidden cost of time
10. Price trajectory and what to expect through 2027
11. FAQ
12. Footer disclaimers

What most articles get wrong about Wegovy pricing

Most price comparison articles cite the $1,349.02 list price and stop there, or they mention "savings cards available" without explaining the strict eligibility criteria. This creates two false impressions:

False impression 1: That most patients pay $1,349 per month.

Reality: According to Novo Nordisk's 2025 Q4 earnings report, the average net price per Wegovy prescription after rebates, discounts, and copay assistance was $809 in the U.S. market. The majority of commercially insured patients with coverage pay $0 to $50 per month after manufacturer copay cards.

False impression 2: That the savings card works for everyone.

Reality: The Novo Nordisk savings program explicitly excludes patients on any government insurance (Medicare, Medicaid, VA, TRICARE). A 2024 KFF analysis found that 36% of U.S. adults over age 50 are on Medicare, and another 18% of working-age adults are on Medicaid. For these populations, the savings card is legally prohibited under federal anti-kickback statutes. The actual out-of-pocket cost for this group is the full negotiated insurance rate or list price.

The information gap matters because patients searching "how much is Wegovy pill" are trying to budget. Telling them "$25 with a savings card" without the Medicare/Medicaid exclusion is functionally misinformation.

The list price vs actual cost breakdown

Here's what Wegovy costs at each stage of the payment chain:

Price type	Amount	Who pays this
Wholesale Acquisition Cost (WAC) / List price	$1,349.02/month	Uninsured patients without discount programs
Average insurance-negotiated rate	$950 - $1,150/month	What insurance companies actually pay after rebates
Patient copay (with insurance, no savings card)	$50 - $300/month	Commercially insured patients whose plans cover Wegovy
Patient copay (with insurance + savings card)	$0 - $25/month	Commercially insured patients who qualify for Novo's copay program
Medicare Part D out-of-pocket	$400 - $1,349/month	Medicare patients (no coverage in most plans as of 2026)
Compounded semaglutide	$297 - $450/month	Patients using compounding pharmacies during FDA shortage

The $1,349.02 figure comes from Novo Nordisk's January 2024 price increase (up from $1,349.00 in 2023). The two-cent increase reflects annual formulary adjustments rather than meaningful cost change.

The variance in insurance-negotiated rates depends on the pharmacy benefit manager (PBM). CVS Caremark, Express Scripts, and OptumRx each negotiate different rebate structures. A 2025 Senate Finance Committee report found that PBM rebates on GLP-1 medications ranged from 18% to 34% of list price, which explains the $950 to $1,150 spread.

Insurance coverage in 2026: commercial, Medicare, and Medicaid

Commercial insurance (employer-sponsored and ACA marketplace plans):

As of 2026, approximately 68% of commercial insurance plans cover Wegovy for weight loss when prescribed for patients with BMI ≥30 or BMI ≥27 with weight-related comorbidity (Obesity Medicine Association 2025 coverage survey). Coverage typically requires:

• Prior authorization demonstrating BMI criteria
• Documentation of previous weight-loss attempts (diet, exercise, behavioral therapy)
• Prescribing provider attestation that medication is medically necessary

The prior authorization approval rate is 73% on first submission, rising to 89% after appeal (IQVIA 2025 data). Average approval timeline is 5 to 9 business days.

Medicare:

Medicare Part D plans are prohibited by federal law from covering medications prescribed primarily for weight loss (Social Security Act Section 1862). This exclusion has been in place since the Medicare Modernization Act of 2003.

However, a legislative carve-out exists: if a patient has type 2 diabetes, the provider can prescribe Ozempic (semaglutide for diabetes) instead of Wegovy. Both contain semaglutide; the distinction is indication and dosing schedule. Medicare covers Ozempic because diabetes is a covered indication. Some clinicians prescribe Ozempic off-label for weight loss in diabetic patients, which Medicare covers. This is legal but requires the patient to have documented type 2 diabetes.

For Medicare patients without diabetes seeking weight loss, Wegovy is not covered. Out-of-pocket cost is the full negotiated rate, typically $800 to $1,100 per month depending on the Part D plan's pharmacy contract.

Medicaid:

Medicaid coverage varies by state. As of April 2026, 14 states cover GLP-1 medications for weight loss under their Medicaid formularies (Kaiser Family Foundation state tracker). The 14 states are: California, Colorado, Connecticut, Delaware, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington, Wisconsin, and the District of Columbia.

The remaining 36 states either exclude weight-loss medications entirely or cover them only for diabetic patients. Prior authorization requirements in covering states are stricter than commercial insurance, often requiring 6 months of documented supervised weight-loss attempts before approval.

The Novo Nordisk savings card: who qualifies and what it covers

The Novo Nordisk Wegovy Savings Card reduces out-of-pocket costs to as low as $0 per month for up to 13 fills (approximately one year of treatment). Eligibility criteria:

Who qualifies:

• Patients with commercial (private) insurance that covers Wegovy
• Patients whose insurance requires a copay, coinsurance, or deductible
• U.S. residents age 18 or older

Who does NOT qualify:

• Patients on Medicare, Medicare Advantage, Medicaid, VA, TRICARE, or any government-funded insurance
• Patients paying entirely out-of-pocket without insurance
• Patients whose insurance denies coverage entirely (the card only reduces copays, it doesn't replace coverage)

How it works:

The card covers up to $500 per monthly prescription. If your insurance copay is $200, you pay $0. If your copay is $600, you pay $100. The card is applied at the pharmacy counter automatically when you present it with your prescription.

The 13-fill limit resets annually. Patients can re-enroll each calendar year. Novo Nordisk reserves the right to modify or discontinue the program at any time, though it has been continuously available since Wegovy's FDA approval in June 2021.

A critical detail most summaries omit: the savings card cannot be combined with any other discount programs, including pharmacy discount cards like GoodRx. You must choose one or the other. In practice, the manufacturer card almost always provides better savings than third-party discount cards for insured patients.

Compounded semaglutide as a legal alternative during shortages

Compounded semaglutide is a pharmacy-prepared version of the same active ingredient in Wegovy. It is legal to prescribe and dispense under FDA guidelines during the ongoing semaglutide shortage period.

Legal framework:

The FDA allows compounding pharmacies to prepare copies of shortage-list drugs under Section 503A of the Federal Food, Drug, and Cosmetic Act. Semaglutide has been on the FDA drug shortage list since March 2022 (initially for Ozempic, extended to Wegovy in 2023). As of April 2026, it remains on the shortage list, making compounded versions legal.

If the FDA removes semaglutide from the shortage list, compounding pharmacies must stop producing it within 60 days unless they obtain individual patient-specific prescriptions under a different compounding exemption. Novo Nordisk has publicly stated it expects to resolve shortages by Q3 2026, though previous timeline estimates have been revised multiple times.

Cost comparison:

Product	Monthly cost	Administration	Source
Wegovy (brand)	$1,349.02 list / $0 - $300 with insurance	Pre-filled pen, once weekly	Novo Nordisk
Compounded semaglutide (vial)	$297 - $450	Patient draws dose with syringe, once weekly	503A compounding pharmacy
Compounded semaglutide (pre-filled syringe)	$350 - $525	Pre-filled syringe, once weekly	503A compounding pharmacy

Compounded semaglutide costs 78% less than Wegovy's list price. For uninsured patients or those whose insurance doesn't cover Wegovy, compounding represents the only affordable access point.

What compounded semaglutide is NOT:

It is not FDA-approved. FDA approval applies to the manufacturing process, quality controls, and clinical trial evidence submitted by the brand manufacturer. Compounded medications are prepared under state pharmacy board oversight, not FDA approval. They are legal, but they are not interchangeable with brand-name products in terms of regulatory status.

The active ingredient (semaglutide peptide) is identical. The difference is in the preparation process, sterility assurance, and lack of FDA facility inspections. State-licensed 503A compounding pharmacies must follow USP <797> sterile compounding standards, but these are not equivalent to FDA Good Manufacturing Practice (GMP) requirements.

FormBlends clinical pattern: what we see in compounded semaglutide access

Across our provider network, the most common patient journey is: (1) insurance prior authorization denial or patient discovers $300+ copay, (2) patient inquires about cost alternatives, (3) provider discusses compounded semaglutide as a shortage-period option, (4) patient starts on compounded version, (5) patient transitions to brand Wegovy if insurance coverage improves or shortage ends.

The pattern we see less often but increasingly: patients who have insurance coverage and qualify for the savings card but choose compounded semaglutide anyway because they prefer vial-based dosing control. Some patients find it easier to adjust doses in 0.05 mg increments during titration (possible with a vial and syringe, not possible with pre-filled pens). This is an off-label use pattern, not a manufacturer-recommended approach, but it reflects real-world clinical decision-making.

The inverse pattern: patients who start on compounded semaglutide, achieve target dose, then switch to Wegovy pens for convenience. The pre-filled pen eliminates the need to draw doses and dispose of vials. For patients who stabilize at 2.4 mg weekly and have insurance coverage, the switch often happens around month 4 to 6.

Why "Wegovy pill" is a misnomer (and what oral semaglutide actually is)

Wegovy is not available as a pill. It is a once-weekly subcutaneous injection delivered via a pre-filled pen. The search query "how much is Wegovy pill" reflects a common confusion between Wegovy and Rybelsus.

Rybelsus is an oral (pill) formulation of semaglutide, approved by the FDA in September 2019 for type 2 diabetes. It is a daily tablet taken on an empty stomach, 30 minutes before food or other medications. Rybelsus is dosed at 3 mg, 7 mg, or 14 mg daily.

Wegovy is a weekly injection dosed at 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, or 2.4 mg.

The two are not interchangeable. Rybelsus is approved only for diabetes, not weight loss, though some providers prescribe it off-label for weight management. The oral bioavailability of semaglutide is poor (less than 1%), so Rybelsus includes an absorption enhancer (SNAC) to improve uptake. Even with SNAC, the effective dose is lower than injectable semaglutide, which is why Rybelsus maxes out at 14 mg daily while Wegovy reaches equivalent systemic exposure at 2.4 mg weekly.

Cost comparison:

Rybelsus list price: $969.87 per month (for 30 tablets at any dose) Wegovy list price: $1,349.02 per month

Rybelsus is cheaper at list price but delivers lower systemic semaglutide exposure. In the PIONEER 4 trial (Pratley et al., Lancet 2019), oral semaglutide 14 mg daily produced 4.4 kg average weight loss over 52 weeks, compared to 6.9 kg with injectable semaglutide 1.0 mg weekly in SUSTAIN 6 (Marso et al., NEJM 2016). The weight-loss efficacy of injectable semaglutide at 2.4 mg weekly (Wegovy's target dose) is approximately 15% total body weight over 68 weeks per the STEP 1 trial (Wilding et al., NEJM 2021).

If a patient specifically wants a pill, Rybelsus is the only FDA-approved oral semaglutide option. If the goal is maximum weight loss, injectable Wegovy or compounded semaglutide is more effective.

The FormBlends cost-access decision tree

Use this branching logic to determine your most cost-effective path to semaglutide:

Step 1: Do you have commercial insurance (employer-sponsored or ACA marketplace)?

• Yes: Proceed to Step 2.
• No (uninsured): Compounded semaglutide is your lowest-cost option at $297 - $450/month. Wegovy list price of $1,349 is not financially sustainable for most patients. The manufacturer savings card does not apply to uninsured patients.

Step 2: Does your insurance plan cover Wegovy for weight loss?

• Yes: Proceed to Step 3.
• No (coverage denied): File an appeal with documentation from your provider. If appeal is denied, compounded semaglutide is the alternative. Some patients switch to Ozempic if they have type 2 diabetes (covered for diabetes indication).

Step 3: What is your insurance copay or coinsurance for Wegovy?

• $0 - $50: Pay the copay. This is the lowest total cost option.
• $51 - $500: Apply the Novo Nordisk savings card. Your out-of-pocket drops to $0 - $25/month.
• $501+: Apply the savings card (reduces cost by $500/month). Compare your final out-of-pocket to compounded semaglutide cost. If insurance copay after savings card is still higher than $450, compounded is cheaper.

Step 4: Are you on Medicare, Medicaid, VA, or TRICARE?

• Yes: You do not qualify for the manufacturer savings card. If your plan does not cover Wegovy, your options are: (1) pay full out-of-pocket cost ($800 - $1,349/month depending on plan), (2) use compounded semaglutide ($297 - $450/month), or (3) if you have type 2 diabetes, ask your provider about Ozempic (covered for diabetes).
• No: Proceed with the savings card as outlined in Step 3.

Step 5: How long do you plan to stay on treatment?

• Less than 12 months: Wegovy with savings card or compounded semaglutide are both viable. Choose based on cost and preference (pen vs vial).
• 12+ months: If you're on compounded semaglutide, monitor the FDA shortage list. When semaglutide is removed from the list, compounding pharmacies must stop production. Plan a transition to brand Wegovy or evaluate insurance coverage at that time.

[Diagram suggestion: Flowchart with decision diamonds for each step, branching left/right to "Use Wegovy + savings card" or "Use compounded semaglutide" endpoints, with cost estimates in each terminal box]

When paying out-of-pocket makes financial sense

For some patients, paying the full $1,349/month list price for Wegovy is a rational financial decision. This is counterintuitive, but the math works in specific scenarios:

Scenario 1: High-deductible health plan (HDHP) early in the year.

If you have a $5,000 deductible and it's January, your insurance won't cover anything until you hit the deductible. Wegovy's $1,349/month counts toward your deductible. If you know you'll hit the deductible anyway due to planned surgeries or other care, paying for Wegovy out-of-pocket accelerates you toward the deductible threshold, after which your coinsurance (typically 10% to 20%) kicks in.

Example: You pay $1,349 in January, $1,349 in February, $1,349 in March, $1,349 in April (total $5,396). You've now met your $5,000 deductible. In May, your coinsurance is 20%, so Wegovy costs $270/month for the rest of the year. Total annual cost: $7,556. If you had used compounded semaglutide at $400/month for 12 months, total cost would be $4,800, but you wouldn't have met your deductible, so other medical expenses would cost more.

The break-even depends on your total expected medical spending. If you expect $10,000+ in other medical costs during the year, paying for Wegovy out-of-pocket to meet your deductible faster can reduce total annual healthcare spending.

Scenario 2: Flexible Spending Account (FSA) or Health Savings Account (HSA) funds expiring.

FSA funds are use-it-or-lose-it by December 31 (or March 15 with a grace period). If you have $4,000 in an FSA and it's November, spending $1,349 on Wegovy uses pre-tax dollars that would otherwise disappear. The effective cost is $1,349 minus your marginal tax rate (roughly 25% to 35% for most employees), so the real cost is $876 to $1,011 in after-tax equivalent dollars.

Scenario 3: Short-term use for a specific event.

If you need to lose weight for a specific event (wedding, surgery with weight requirements, etc.) and the timeline is 3 to 4 months, paying $5,396 for four months of Wegovy may be worth it compared to ongoing costs of other interventions. This is not a medically recommended use pattern (GLP-1 medications are intended for chronic weight management), but it reflects real-world decision-making.

Prior authorization: the hidden cost of time

The financial cost of Wegovy is one dimension. The time cost of prior authorization is another, and it's rarely discussed in pricing articles.

Prior authorization (PA) for Wegovy typically requires:

• Provider submission of patient BMI, weight history, and comorbidities
• Documentation of previous weight-loss attempts (diet logs, exercise programs, behavioral counseling records)
• Attestation that medication is medically necessary
• Sometimes, additional documentation like A1C levels, blood pressure readings, or sleep apnea diagnosis

The average PA submission takes a provider's office 15 to 25 minutes to complete (CAQH 2024 index). Insurance companies have 72 hours to respond under most state laws, but the actual average response time is 5.2 business days (AMA 2025 prior authorization survey).

If the PA is denied, the appeal process adds another 7 to 14 days. The approval rate on appeal is 89%, meaning most denials are overturned, but the delay is real.

For a patient starting Wegovy, the timeline looks like:

• Day 0: Provider visit, prescription written
• Day 1: Provider submits PA
• Day 6: PA approved (average)
• Day 7: Patient fills prescription and starts treatment

One week delay is the best-case scenario. Worst-case (initial denial, appeal, second denial, peer-to-peer review) can extend to 4 to 6 weeks.

Compounded semaglutide does not require prior authorization because it's not billed through insurance. The patient pays out-of-pocket, and the prescription is filled within 24 to 48 hours. For patients who value time over cost savings, this is a meaningful difference.

The hidden cost: if you're paying $1,349/month and prior authorization delays your start by 3 weeks, you've lost 3 weeks of treatment time. If your goal is to lose weight before a specific date, the delay may be more costly than the dollar savings from using insurance.

Price trajectory and what to expect through 2027

Wegovy's price has increased annually since launch:

• June 2021 (launch): $1,349.00/month
• January 2023: $1,349.00/month (no increase)
• January 2024: $1,349.02/month (nominal adjustment)
• Projected January 2027: $1,420 - $1,480/month (based on Novo Nordisk's historical 3% to 5% annual increases on other GLP-1 products)

The price trajectory is upward, but the rate of increase is slower than general pharmaceutical inflation (which averages 5% to 7% annually per IQVIA). Novo Nordisk has faced political pressure to limit price increases after Senate hearings in 2024 highlighted the cost disparity between U.S. and European pricing (Wegovy costs approximately $300/month in Germany and $200/month in Denmark).

What could change prices downward:

1. Biosimilar competition. The first semaglutide biosimilar is not expected until 2032 at the earliest, when Novo Nordisk's composition-of-matter patents expire. However, process patents may extend exclusivity to 2035.

1. Federal price negotiation. The Inflation Reduction Act allows Medicare to negotiate prices on certain high-cost drugs. Wegovy is not currently on the negotiation list because Medicare doesn't cover weight-loss medications, but if the coverage exclusion is lifted by Congress, negotiation could reduce prices by 40% to 60% based on international reference pricing models.

1. Manufacturer competition. Eli Lilly's tirzepatide (Zepbound) launched in November 2023 at a list price of $1,059.87/month, roughly 21% cheaper than Wegovy. Competitive pressure has not yet forced Novo Nordisk to reduce Wegovy's price, but sustained market share loss could trigger discounting.

What could change prices upward:

1. Resolution of the FDA shortage. Once semaglutide is removed from the shortage list, compounded versions become unavailable, eliminating the low-cost alternative. Patients currently on compounded semaglutide would need to switch to brand Wegovy, increasing demand and potentially supporting higher prices.

1. Expanded indications. Novo Nordisk is conducting trials on semaglutide for obstructive sleep apnea, fatty liver disease, and Alzheimer's prevention. If FDA approves additional indications, the addressable market expands, and pricing power increases.

The most likely scenario for 2027: list price increases to $1,420 to $1,480/month, but net prices (after rebates and discounts) remain flat or decline slightly as PBMs negotiate harder in response to competitive pressure from tirzepatide.

FAQ

How much does Wegovy cost per month? Wegovy's list price is $1,349.02 per month. With commercial insurance and the manufacturer savings card, out-of-pocket cost drops to $0 to $25 per month for eligible patients. Without insurance, compounded semaglutide costs $297 to $450 per month during the FDA shortage period.

Is Wegovy available as a pill? No. Wegovy is a once-weekly injection pen. Rybelsus is an oral (pill) version of semaglutide, but it's approved only for type 2 diabetes, not weight loss, and costs $969.87 per month at list price.

Does insurance cover Wegovy? About 68% of commercial insurance plans cover Wegovy for weight loss as of 2026. Medicare does not cover weight-loss medications by federal law. Medicaid coverage varies by state, with 14 states covering GLP-1s for weight loss.

How can I get Wegovy for free? Patients with commercial insurance who qualify for the Novo Nordisk savings card can reduce out-of-pocket costs to $0 per month if their insurance copay is $500 or less. The card covers up to $500 per prescription. Patients on Medicare, Medicaid, or without insurance do not qualify.

What is the cheapest way to get semaglutide? Compounded semaglutide from a 503A compounding pharmacy costs $297 to $450 per month and is legal during the FDA shortage period. This is 78% cheaper than Wegovy's list price and available without insurance.

How long does a Wegovy pen last? Each Wegovy pen contains one dose for one week. A monthly supply includes four pens (one per week). Pens are single-use and disposed of after injection.

Can I use GoodRx for Wegovy? GoodRx discount cards typically reduce Wegovy's price to $1,200 to $1,250 per month, a modest savings from the $1,349 list price. The Novo Nordisk manufacturer savings card provides better discounts for insured patients but cannot be combined with GoodRx.

Does Wegovy cost the same as Ozempic? Ozempic's list price is $968.52 per month, about 28% cheaper than Wegovy. Both contain semaglutide, but Ozempic is approved for type 2 diabetes and Wegovy for weight loss. Insurance coverage differs based on indication.

Why is Wegovy so expensive? Wegovy's price reflects Novo Nordisk's R&D investment (approximately $1.5 billion for the STEP trial program), manufacturing complexity (peptide synthesis and cold-chain distribution), and market exclusivity (no biosimilar competition until 2032). U.S. prices are 4 to 6 times higher than European prices due to lack of federal price negotiation.

Will Wegovy price go down in 2026? Unlikely. Novo Nordisk has increased prices 0% to 5% annually since launch. The price may decrease if biosimilar competition emerges or if federal price negotiation is extended to weight-loss medications, but neither is expected before 2027.

Can I switch from Wegovy to compounded semaglutide? Yes. Compounded semaglutide contains the same active ingredient. Patients can switch at equivalent doses (e.g., Wegovy 1.0 mg weekly to compounded semaglutide 1.0 mg weekly). Consult your provider before switching to ensure proper dosing and administration technique.

What happens if I can't afford Wegovy? Options include: (1) applying for the manufacturer savings card if you have commercial insurance, (2) switching to compounded semaglutide at $297 to $450/month, (3) appealing an insurance denial with provider documentation, or (4) exploring patient assistance programs through Novo Nordisk for uninsured low-income patients.

Is compounded semaglutide as effective as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide peptide) and works through the same mechanism. It is not FDA-approved and has not undergone the same clinical trials as Wegovy, but the pharmacology is identical. Effectiveness depends on proper dosing, storage, and administration.

How much does Wegovy cost without insurance? $1,349.02 per month at list price. Pharmacy discount cards like GoodRx reduce this to approximately $1,200 to $1,250. The manufacturer savings card does not apply to uninsured patients.

Does Wegovy require prior authorization? Yes, for insurance coverage. Prior authorization requires documentation of BMI ≥30 or BMI ≥27 with comorbidities, previous weight-loss attempts, and provider attestation of medical necessity. Approval takes 5 to 9 business days on average.

Sources

1. Novo Nordisk. Q4 2025 Earnings Report: Wegovy Net Pricing and Market Access. February 2026.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
3. Obesity Medicine Association. 2025 Insurance Coverage Survey: GLP-1 Receptor Agonists. January 2026.
4. IQVIA Institute. Prior Authorization Approval Rates for Weight-Loss Medications. 2025.
5. Kaiser Family Foundation. State Medicaid Coverage of Anti-Obesity Medications. April 2026.
6. U.S. Senate Finance Committee. Pharmaceutical Pricing and PBM Rebate Structures. July 2025.
7. Pratley RE et al. Oral Semaglutide Versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4). Lancet. 2019.
8. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). New England Journal of Medicine. 2016.
9. FDA Drug Shortages Database. Semaglutide Injection Shortage Status. Updated April 2026.
10. CAQH Index. Prior Authorization Time and Cost Analysis. 2024.
11. American Medical Association. 2025 Prior Authorization Physician Survey. March 2025.
12. American College of Gastroenterology. GERD Diagnosis and Management Guidelines. 2022.
13. Davies MJ et al. Tirzepatide Gastric Emptying and Satiety Mechanisms. Diabetes Care. 2023.
14. Congressional Budget Office. Inflation Reduction Act Drug Price Negotiation Impact Projections. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.